首頁 > 市場調查報告書 > 製藥

消化器

市場調查報告書

商品編碼

1699448

嗜伊紅性食道炎市場：市場規模、佔有率、前景、按藥物類別、分銷管道和地區分類的機會分析 - 2025 年至 2032 年

Eosinophilic Esophagitis Market, by Drug Class, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032

出版日期: 2025年03月04日 | 出版商:

Coherent Market Insights | 英文 207 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年全球嗜伊紅性食道炎市場規模估計為 2.391 億美元，預計到 2032 年將達到 17.974 億美元，2025 年至 2032 年的複合年成長率為 33.4%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	2.391億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年複合年成長率：	33.40%	2032年價值預測	17.974億美元

數字。嗜伊紅性食道炎各地區市場佔有率（%）2025年

嗜伊紅性食道炎是一種慢性疾病，可透過類固醇和質子幫浦阻斷劑等抑酸藥物治療。類固醇有助於減輕發炎。外用類固醇以吸入或液體藥物的形式給藥。如果出現嚴重的吞嚥問題或體重減輕，則需要服用口服類固醇。質子幫浦阻斷劑可改善逆流症狀並減少發炎。

市場動態

人們對嗜伊紅性食道炎治療必要性的認知不斷提高，將導致對治療藥物的需求增加。因此，主要市場參與者正在開發新的治療方法來滿足對 EoE 藥物的需求。例如，全球生物製藥公司賽諾菲 (Sanofi SA) 正在進行 Dupixent (dupilumab) 的 3 期臨床試驗，預計將於 2024 年完成。此外，改善 EoE 管理的創新產品的出現預計將推動全球市場的成長。例如，2021年12月，日本跨國工業工業株式會社收到了美國食品藥物管理局（FDA）針對嗜伊紅性食道炎接受TAK-721（Budesonide口服混懸液）發出的完整回覆函。 2021年6月，Etrasimod獲得美國FDA頒發的孤兒藥資格（ODD）。 Etrasimod 正在由美國生物製藥公司 Arena Pharmaceuticals, Inc. 進行研究。此外，嗜伊紅性食道炎盛行率的不斷上升可能會促進市場成長。例如，根據2018年7月發表在《沙烏地醫學雜誌》上的一項研究，嗜伊紅性食道炎是一種新興疾病，在沙烏地阿拉伯兒童的發生率正在上升。

本研究的主要特點

本報告對預測期（2025-2032 年）全球嗜伊紅性食道炎市場規模進行了詳細分析，以 2024 年為基準年。
它揭示了不同領域的潛在商機，並解釋了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
全球嗜伊紅性食道炎市場的主要企業是根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數進行的分析。
本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球嗜伊紅性食道炎市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。
相關人員可以透過分析全球嗜伊紅性食道炎市場中使用的各種策略矩陣來簡化決策。

熱圖分析
市場佔有率分析
- Ellodi Pharmaceuticals.
- EsoCap AG
- GlaxoSmithKline plc.
- Teva Pharmaceutical Industries Ltd
- Cipla Limited
- Sun Pharmaceutical Industries Limited
- AstraZeneca Plc
- Sanofi SA
- Arena Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Revolo Biotherapeutics
- Allakos Inc.
- Bristol-Myers Squibb Co
- Calypso Biotech
- DBV Technologies
- Landos Biopharma, Inc.
- Glenmark Pharmaceuticals
- Alkem Laboratories Ltd.
- Quorum Innovations LLC
- Falk Pharma GmbH

第9章分析師建議

命運之輪
分析師觀點
一致的機會圖

第 10 章章節

參考
調查方法

簡介目錄

Product Code: CMI4909

Global Eosinophilic Esophagitis Market is estimated to be valued at USD 239.1 Mn in 2025 and is expected to reach USD 1,797.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 33.4% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 239.1 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	33.40%	2032 Value Projection:	USD 1,797.4 Mn

Figure. Eosinophilic Esophagitis Market Share (%), By Region 2025

Eosinophilic esophagitis is a chronic condition which is treated with the help of steroids and acid suppressants such as proton pump inhibitors. Steroids help control the inflammation. Topical steroids are administered as a inhaler or as a liquid. Oral steroids may be prescribed to treat people who have serious swallowing problems or weight loss. Proton pump inhibitors help with reflux symptoms and decrease inflammation.

Market Dynamics

Growing awareness regarding eosinophilic esophagitis leads to an increase in demand for treatment products. Thus, key market players are engaged in developing newer treatments and addressing the demand for EoE treatment products. For instance, Sanofi S.A. a global biopharmaceutical company engaged in conducting a phase 3 clinical trial for Dupixent (dupilumab) and is estimated to complete by 2024. Additionally, upcoming innovative products to improve the management of EoE are anticipated to drive the global market growth. For instance, in December 2021, Takeda Pharmaceutical Company Limited a Japanese multinational pharmaceutical company received a Complete Response Letter (CRL) for TAK-721 (budesonide oral suspension) from the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis. In June 2021, the U.S. FDA granted Orphan Drug Designation (ODD) for Etrasimod. Etrasimod had been investigated by Arena Pharmaceuticals, Inc. an American biopharmaceutical company. Moreover, an increase in the prevalence of eosinophilic esophagitis is likely boost the market growth. For instance, according to a study published in the Saudi Medical Journal in July 2018, eosinophilic esophagitis is an emerging disease and has an increasing incidence in children in Saudi Arabia.

Key features of the study:

This report provides an in-depth analysis of the global eosinophilic esophagitis market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global eosinophilic esophagitis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global eosinophilic esophagitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global eosinophilic esophagitis market

Detailed Segmentation:

Global Eosinophilic Esophagitis Market, By Drug Class:
- Corticosteroids
- Budesonide
- Jorveza
- Off-label budesonide
- Fluticasone
- Proton Pump Inhibitor (PPI)
- Omeprazole
- Esomeprazole
- Others
- Late Stage Pipeline Drugs
- Dupixent
- APT-1011
- Lirentelimab (AK002)
- Cendakimab
- Etrasimod
- TAK-721
- Omilancor (BT-11)
Global Eosinophilic Esophagitis Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Eosinophilic Esophagitis Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- GlaxoSmithKline plc
- Ellodi Pharmaceuticals
- EsoCap AG
- Teva Pharmaceutical Industries Ltd.
- Cipla Limited
- Sun Pharmaceutical Industries Limited
- AstraZeneca Plc
- Sanofi S.A.
- Arena Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Revolo Biotherapeutics
- Allakos Inc.
- Bristol-Myers Squibb Co
- Calypso Biotech
- DBV Technologies
- Landos Biopharma, Inc.
- Glenmark Pharmaceuticals
- Alkem Laboratories Ltd.
- Quorum Innovations LLC
- Dr. Falk Pharma GmbH

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Opportunities
Impact Analysis
Pipeline Analysis
Regulatory Scenario
Recent Product Approval/Launch
PEST Analysis
Epidemiology

4. Global Eosinophilic Esophagitis Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply and Demand Analysis
Key Developments

5. Global Eosinophilic Esophagitis Market, By Drug Class, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
  - Budesonide
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
      - Jorveza
        
        1. Introduction
        2. Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
      - Off-label budesonide
        
        1. Introduction
        2. Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Fluticasone
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
Proton Pump Inhibitor (PPI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
  - Omeprazole
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Esomeprazole
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Others
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
Late Stage Pipeline Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
  - Dupixent
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - APT-1012
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Lirentelimab (AK002)
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Cendakimab
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Etrasimod
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - TAK-721
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)
  - Omilancor (BT-11)
    - Introduction
    - Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Million)

6. Global Eosinophilic Esophagitis Market, By Distribution Channel, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)

7. Global Eosinophilic Esophagitis Market, By Region, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2029 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2032
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - U.K.
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- Ellodi Pharmaceuticals.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- EsoCap AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Strategies
- GlaxoSmithKline plc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Cipla Limited
- Sun Pharmaceutical Industries Limited
- AstraZeneca Plc
- Sanofi S.A.
- Arena Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Revolo Biotherapeutics
- Allakos Inc.
- Bristol-Myers Squibb Co
- Calypso Biotech
- DBV Technologies
- Landos Biopharma, Inc.
- Glenmark Pharmaceuticals
- Alkem Laboratories Ltd.
- Quorum Innovations LLC
- Falk Pharma GmbH

9. Analyst Recommendation

Wheel of Fortune
Analyst View
Coherent Opportunity Map

10. Section

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

嗜酸性食道炎市場機會、成長動力、產業趨勢分析與預測 2025 - 2034

嗜伊紅性食道炎治療市場：預測（2025-2030）

FAQ

嗜伊紅性食道炎市場：市場規模、佔有率、前景、按藥物類別、分銷管道和地區分類的機會分析 - 2025 年至 2032 年